Claritev (NYSE:CTEV) SVP Tiffani Misencik Sells 5,812 Shares of Company Stock

Claritev (NYSE:CTEV) SVP Tiffani Misencik sold 5,812 shares of the business’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $23.81, for a total transaction of $138,383.72. Following the sale, the senior vice president owned 107,917 shares of the company’s stock, valued at approximately $2,569,503.77. This represents a 5.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tiffani Misencik also recently made the following trade(s):

• On Friday, August 14th, Tiffani Misencik sold 8,850 shares of Claritev stock. The stock was sold at an average price of $40.07, for a total value of $354,619.50.

Claritev Price Performance

Shares of CTEV traded down $1.80 during trading hours on Friday, hitting $22.06. The stock had a trading volume of 190,576 shares, compared to its average volume of 189,876. Claritev has a 12 month low of $11.50 and a 12 month high of $73.68. The firm has a market capitalization of $373.92 million, a PE ratio of -1.30 and a beta of 0.93. The stock has a fifty day moving average price of $31.65 and a 200 day moving average price of $27.55.

Claritev (NYSE:CTEV) last posted its quarterly earnings data on Friday, August 7th. The company reported $1.41 EPS for the quarter, beating analysts’ consensus estimates of ($4.10) by $5.51. The firm had revenue of $257.48 million for the quarter. As a group, analysts anticipate that Claritev will post -15.13 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on CTEV shares. Piper Sandler reiterated an “overweight” rating and issued a $73.00 price objective on shares of Claritev in a research note on Wednesday, August 12th. Wall Street Zen upgraded shares of Claritev from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Citigroup restated a “buy” rating and set a $45.00 target price (up from $40.00) on shares of Claritev in a research report on Monday, August 10th. Zacks Research raised shares of Claritev from a “strong sell” rating to a “hold” rating in a report on Thursday, August 13th. Finally, Canaccord Genuity Group increased their price target on shares of Claritev from $37.00 to $43.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Claritev currently has an average rating of “Moderate Buy” and a consensus price target of $44.83.

Institutional Trading of Claritev

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp raised its stake in shares of Claritev by 2.5% in the first quarter. Bank of New York Mellon Corp now owns 18,111 shares of the company’s stock worth $296,000 after buying an additional 447 shares during the period. RBF Capital LLC grew its stake in shares of Claritev by 0.8% during the 1st quarter. RBF Capital LLC now owns 135,314 shares of the company’s stock valued at $2,211,000 after acquiring an additional 1,127 shares during the period. Integrated Wealth Concepts LLC bought a new position in shares of Claritev during the 2nd quarter valued at approximately $44,000. State of Wyoming increased its holdings in Claritev by 239.2% in the 1st quarter. State of Wyoming now owns 2,018 shares of the company’s stock worth $33,000 after acquiring an additional 1,423 shares in the last quarter. Finally, Public Employees Retirement System of Ohio purchased a new stake in Claritev in the 1st quarter worth approximately $38,000. Hedge funds and other institutional investors own 87.15% of the company’s stock.

About Claritev

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.